Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Jefferies analyst Eun Yang noted Doptelet sales 'dipped 12% quarter over quarter because of competitive pricing pressure and payer restrictions' and Q2…
Evaluate analysts projected Doptelet could achieve $1.88B in peak sales across approved indications, citing a 'cleaner clinical profile than Promacta' with no…
"Swedish Orphan Biovitrum AB (Sobi) has agreed to acquire US-based Dova Pharmaceuticals in a transaction valued up to $915m," expanding Sobi's haematology…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Sobi agreed to acquire Dova Pharmaceuticals for $27.50/share or approximately $915 million, with an additional $1.50/share CVR linked to FDA label expansion. Lead asset is Doptelet (avatrombopag) for thrombocytopenia in chronic liver disease and chronic ITP. Sobi completed the acquisition by merger on November 12, 2019. The CVR required FDA approval of Doptelet in chemotherapy-induced thrombocytopenia (CIT) by December 31, 2022; that approval was not obtained — the Phase 3 CIT trial reported in 2022 and avatrombopag remains approved only in chronic liver disease and chronic ITP — so the contingent $1.50/share milestone lapsed.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sobi (Swedish Orphan Biovitrum AB) / Dova Pharmaceuticals, Inc. (this deal) | 2019 | $915M | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2019 deals · Hematology deals